AUTHORS
Fjoralba Kristo, MD, MPH, Thibaud Alin, MSc2, Flora Mazerolle, MSc3, Antoine Regnault, PhD4, Janina Jablonski, MSc5, Justin Ferdinandus, MD6, Karolin Behringer, MD7, Peter Borchmann, MD8, Ajibade Ashaye, MD, MS, MBA, MPH9
AFFILIATIONS
1 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
2 Modus Outcomes, Lyon, France
3 Modus Outcomes, Lyon, France
4 Modus Outcomes, Lyon, France
5 Department I of Internal Medicine, German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Cologne, Germany
6 Department I of Internal Medicine, German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Cologne, Germany
7 Department I of Internal Medicine, German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Cologne, Germany
8 Department I of Internal Medicine, German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Cologne, Germany
9 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
ABSTRACT
Introduction: Effective first-line multiagent regimen options remain limited for older patients (pts) with advanced-stage classic Hodgkin lymphoma (AS-cHL) as they are often unable to receive such intensified regimens due to high treatment-related toxicity and age-related comorbidities. In this population, treatment burden can be associated with increased fatigue, deteriorated physical function and overall health-related quality of life (HRQoL). These patients would therefore greatly benefit from treatment options combining high efficacy with minimized treatment burden. Previous results from the randomized HD21 study in pts aged 18-60 years with AS-cHL showed better efficacy and tolerability of BrECADD versus eBEACOPP. BrECADD feasibility as a treatment option for older pts was evaluated in the phase 2, nonrandomized, single-arm cohort of the HD21 study in pts aged 61-75 years. This post-hoc analysis explores pts’ HRQoL using long-term data from the HD21 phase 2 cohort of pts aged 61-75 years (database lock: 01OCT2025).
Methods: The HD21 nonrandomized cohort enrolled 85 pts aged 61-75 years who received four or six 21-day treatment cycles of BrECADD, based on PET results after two cycles (St2). The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire – Core 30 items (QLQ-C30) was administered at baseline, during treatment and up to 48-month follow-up (FU). The rate of available QLQ-C30 questionnaire (number of pts who completed at least one item divided by the total number of pts) was calculated at each visit. Meaningful change in QLQ-C30 Global health/quality of life (GH/QL) score (16.67-point change), Physical functioning (PF) score (13.33-point change), Fatigue (FA) score (11.11-point change), Role functioning (RF) score (16.67-point change), and Social functioning (SF) score (16.67-point change) were described longitudinally.
Results: The PRO analysis set included 55 pts (31 from Germany and 24 from the other countries: 8 from Switzerland, 7 from Austria, 5 from Norway, 3 from Australia, and 1 from Netherlands, sharing overall similar baseline characteristics). The rate of available EORTC QLQ-C30 questionnaire decreased to 69% (N=38) at the end of chemotherapy (EoC), and ranged between 49% (N=27) at 3-month FU to 9% (N=5) at 48-month FU.
An increased percentage of pts experienced meaningfully improved overall health and reduced fatigue compared to baseline over the study, while the percentage of pts with worsening during treatment decreased over the FU. The percentage of pts who experienced a meaningful improvement from baseline in GH/QL score increased during the treatment period, from 18% (10 out of 55 pts [10/55]) at St2 to 37% (13/35) at 24-month FU. In parallel, the percentage of pts with a meaningful deterioration decreased from 25% (14/55) at St2 to 3% (1/35) at 24-month FU. The percentage of pts with a meaningful improvement in FA score increased from 11% (6/55) at St2 to 40% (14/35) at 24-month FU, while those with a meaningful deterioration decreased from 40% (22/55) at St2 to 20% (7/35) at 24-month FU.
A similar trend was observed in pts’ functioning. The percentage of pts with a meaningful improvement from baseline in their PF score increased from 5% (3/55) at St2 to 17% (6/35) at 24-month FU, while the percentage of pts with a meaningful deterioration in PF score decreased over time from 44% (24/55) at St2 to 9% (3/35) at 24-month FU. The percentage of pts with a meaningful improvement in SF score increased from 16% (9/55) at St2 to 31% (11/35) at 24-month FU, while those with a meaningful deterioration decreased from 31% (17/55) at St2 to 11% (4/35) at 24-month FU. A similar pattern was observed for the RF score.
The high rate of missing data and quick decrease in available PRO data in the already small nonrandomized pt cohort and risk of selection bias imposes cautious interpretation of these results.
Conclusion: Treatment with BrECADD of a cohort of 55 pts with AS-cHL aged 61-75 years was associated with improvement in HRQoL, notably fatigue and physical functioning, with benefit sustained through two years after treatment completion. Only a small percentage of patients reported meaningful deterioration in HRQoL during treatment, which tended to decrease over the FU.
DISCLOSURES
Fjoralba Kristo, MD, MPH: Takeda - Current equity holder in publicly-traded company; Takeda - Current Employment